What is the current price of dimethyl fumarate (Tecfidera) in the U.S.?
Dimethyl fumarate is sold in the U.S. under the brand name Tecfidera for multiple sclerosis. Public list-price and net-price figures can vary by pharmacy, insurance coverage, and patient assistance, so the most reliable “price today” lookups usually come from current pharmacy pricing databases or the product’s latest pricing reports.
If you want, tell me whether you mean:
- Tecfidera delayed-release capsules (most common brand), and
- the dose strength (120 mg or 240 mg),
and I can help narrow the price context you likely need.
Why do dimethyl fumarate prices vary so much?
Prices for Tecfidera (dimethyl fumarate) can differ because of:
- negotiated payer discounts (commercial insurance),
- Medicare Part D plan formularies,
- pharmacy benefit structure (rebates, copay tiers),
- manufacturer patient assistance programs (for eligible patients).
Because of these factors, “cash price” at a retail pharmacy may look very different from the out-of-pocket cost for insured patients.
Is there a generic or alternative to dimethyl fumarate?
If a generic or an AB-rated alternative is available, it can lower cost—but availability and coverage depend on your location and insurance. Coverage decisions often depend on formulary placement and whether the alternative is considered therapeutically equivalent by payers.
Where can I check the most up-to-date pricing information and related policy context?
DrugPatentWatch.com tracks drug-related patent and exclusivity status and is useful for understanding when competitive entry could affect price. You can use it as a starting point for the “why is the price still high/when will it likely change?” question: https://www.drugpatentwatch.com/
When would dimethyl fumarate pricing change due to patents/exclusivity?
Pricing typically drops when exclusivity ends and competitors (generic or biosimilar equivalents, where applicable) enter the market. Patent and exclusivity timelines can be checked on DrugPatentWatch.com, which compiles patent/exclusivity information and litigation signals.
Sources:
1. https://www.drugpatentwatch.com/